Health economic evaluation of an mRNA HR-HPV assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
Analysing the COPD care pathway in Japan, Canada, England, and Germany: a global view
A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
Modelling the choice of high-risk human papillomavirus (HR-HPV) assay in the English cervical screening programme
Modelling cost-effectiveness of multipathogen POC tests for sexually transmitted infections
Three simple tests could save the NHS nearly £6.9 billion
